Zytiga 250 mg Alternative – Abiraxen (Abiraterone acetate) 250 mg Tablet | Everest Pharmaceuticals
Abiraxen 250 mg (Abiraterone acetate) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Zytiga (Janssen). It belongs to the androgen biosynthesis inhibitor class and is used in selected advanced prostate cancer regimens with corticosteroid therapy.
Active ingredient: Abiraterone acetate
Strength: 250 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Product Overview
Abiraxen 250 mg Tablet by Everest Pharmaceuticals Ltd., Bangladesh contains Abiraterone acetate. It is listed here as a same-ingredient branded option for people researching Zytiga, a reference brand associated with Janssen. Abiraxen and Zytiga must not be assumed to have identical formulations, approved indications or demonstrated bioequivalence. This page refers only to the 250 mg strength.
Abiraxen vs. Zytiga – Originator / Reference Brand Comparison
Zytiga is a widely recognized reference brand for Abiraterone acetate associated with Janssen. Abiraxen is the Everest Pharmaceuticals product listed in this catalogue. The comparison identifies a shared active ingredient; the exact strength, dosage form, excipients, product registration and interchangeability must be checked for each marketed presentation. Reference-brand naming does not mean Abiraxen is manufactured by Janssen, approved by the same regulator or automatically substitutable. In particular, different formulations and release forms must not be treated as interchangeable.
Composition and Active Ingredient
Active ingredient: Abiraterone acetate
Strength: 250 mg
Dosage form: Tablet
Pharmacological class: androgen biosynthesis inhibitor
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.
The complete inactive ingredient list and product-specific pack presentation require confirmation from the manufacturer’s current label.
Therapeutic Uses and Indications
Abiraterone acetate is used in selected advanced prostate cancer regimens with corticosteroid therapy. The applicable indication depends on the specific formulation, country authorization, diagnosis, biomarker results where relevant, and previous treatment. The information describes the generic medicine’s recognized therapeutic context; it does not independently verify every indication for the Everest product in every country. Only a specialist can establish whether the medicine is suitable for an individual patient.
Mechanism of Action – How Abiraterone acetate Works
Abiraterone acetate is a androgen biosynthesis inhibitor. In general, it inhibits CYP17-mediated androgen synthesis. The medicine’s effects depend on disease biology, dosing, combinations with other treatments and patient factors. Mechanism of action alone does not establish effectiveness for an individual patient or a particular unapproved use.
Dosage and Administration
The product contains 250 mg per tablet; this is not a recommended daily dose. A prescriber determines the appropriate regimen based on the indication, laboratory results, organ function, interactions and adverse effects. Follow the approved product leaflet for food instructions, missed doses, handling and treatment duration. Never adjust the dose or replace another brand or strength without medical authorization.
Contraindications
Do not use this medicine if a clinician has identified a contraindication, including known hypersensitivity to its ingredients where applicable. Additional restrictions vary by active ingredient, formulation, disease and pregnancy status. The complete contraindication list must be checked in the locally approved prescribing information before treatment.
Warnings and Precautions
Important precautions for Abiraterone acetate include: high blood pressure, low potassium, fluid retention and liver injury. Patients should discuss liver or kidney disease, cardiac conditions, blood count abnormalities, pregnancy plans and concurrent treatments with the prescribing team. Depending on the medicine, regular laboratory testing, electrocardiograms, blood pressure checks or other monitoring may be necessary. The product’s official safety labeling governs specific requirements.
Possible Side Effects
The adverse-effect profile of Abiraterone acetate varies by indication and combination regimen. Relevant potential adverse effects and serious risks include high blood pressure, low potassium, fluid retention and liver injury. Other symptoms can occur, and not everyone experiences the same effects. Seek prompt medical attention for severe, unexpected or rapidly worsening symptoms, and consult the current patient leaflet for urgent warning signs.
Drug Interactions
Prescription medicines, over-the-counter products, herbal supplements and certain foods can change the effectiveness or safety of Abiraterone acetate. The interaction profile is ingredient-specific; a clinician or pharmacist should review all concurrent treatments before therapy. Never add, stop or change another medicine based solely on this online description.
Pregnancy, Fertility and Breastfeeding
Many anticancer and hematology medicines can harm a developing fetus or require specific contraception and breastfeeding precautions. People who are pregnant, planning pregnancy or breastfeeding should not start Abiraterone acetate without specialist advice. Exact pregnancy testing, contraception duration and breastfeeding restrictions must be checked in the official labeling for this medicine.
Storage and Handling
Store the medicine according to the instructions on the actual Everest Pharmaceuticals pack, protecting it from unsuitable heat, humidity and light as directed. Keep it in its original packaging, away from children, and do not use expired or damaged packs. Some anticancer medicines require additional safe-handling precautions.
Why Is Abiraxen Listed as an Alternative to Zytiga?
This listing helps customers identify an Everest Pharmaceuticals product containing Abiraterone acetate while researching Zytiga. The term alternative refers to the active ingredient and therapeutic context, not proof of identical regulatory status, bioequivalence or permission to substitute. Confirm the exact formulation and strength with the treating clinician and check the destination country’s medicine registration and import rules.
Manufacturer Information
Listed brand: Abiraxen
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Reference brand: Zytiga
Reference company: Janssen
Generic ingredient: Abiraterone acetate
Strength: 250 mg
Dosage form: Tablet
Therapeutic class: androgen biosynthesis inhibitor
Frequently Asked Questions
What is Abiraxen 250 mg?
It is an Everest Pharmaceuticals tablet containing Abiraterone acetate 250 mg.
Is Abiraxen the same as Zytiga?
They are presented as brands associated with Abiraterone acetate, but brand, formulation, approvals and product-specific evidence can differ. No automatic equivalence is established.
What is Abiraterone acetate used for?
Abiraterone acetate is used in selected advanced prostate cancer regimens with corticosteroid therapy, subject to the applicable label and clinical assessment.
How does Abiraterone acetate work?
It inhibits CYP17-mediated androgen synthesis.
Can I switch strengths or brands myself?
No. A licensed prescriber or pharmacist must assess any substitution.
Is a prescription needed?
Yes. This medicine requires appropriate prescription and specialist oversight under applicable laws.
Important Medical Disclaimer
This page provides educational pharmaceutical identification information, not personal medical advice. Prescribing, dispensing and any substitution must be based on current authorized labeling, patient assessment and applicable laws. Product-specific registration and equivalence have not been independently established by this catalogue.
| Generic Name | Abiraterone acetate |
|---|---|
| Strength | 250 mg |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Pack Size | 4 × 7 tablets |
Related products
Alecensa 150 mg Alternative – Alecnib (Alectinib) 150 mg Capsule | Everest Pharmaceuticals
Alecnib 150 mg (Alectinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Alecensa (Roche / Genentech). It belongs to the ALK inhibitor class and is used in appropriately tested ALK-positive non-small cell lung cancer.
Active ingredient: Alectinib
Strength: 150 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Casodex 50 mg Alternative – Calupros (Bicalutamide) 50 mg Tablet | Everest Pharmaceuticals
Calupros 50 mg (Bicalutamide) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Casodex (AstraZeneca). It belongs to the nonsteroidal antiandrogen class and is used in selected prostate cancer hormonal treatment regimens.
Active ingredient: Bicalutamide
Strength: 50 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Ibrance 125 mg Alternative – Palboxen (Palbociclib) 125 mg Capsule | Everest Pharmaceuticals
Palboxen 125 mg (Palbociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Ibrance (Pfizer). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Palbociclib
Strength: 125 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lorbrena / Lorviqua 100 mg Alternative – Lorbrexen (Lorlatinib) 100 mg Tablet | Everest Pharmaceuticals
Lorbrexen 100 mg (Lorlatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lorbrena / Lorviqua (Pfizer). It belongs to the ALK inhibitor class and is used in selected ALK-positive metastatic non-small cell lung cancer.
Active ingredient: Lorlatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tagrisso 80 mg Alternative – Osimert (Osimertinib) 80 mg Tablet | Everest Pharmaceuticals
Osimert 80 mg (Osimertinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tagrisso (AstraZeneca). It belongs to the EGFR tyrosine kinase inhibitor class and is used in selected EGFR-mutated non-small cell lung cancer.
Active ingredient: Osimertinib
Strength: 80 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Votrient 200 mg Alternative – Pazorest (Pazopanib) 200 mg Tablet | Everest Pharmaceuticals
Pazorest 200 mg (Pazopanib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Votrient (Novartis). It belongs to the multitarget kinase inhibitor class and is used in selected advanced renal cell carcinoma and soft tissue sarcoma.
Active ingredient: Pazopanib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Xalkori 250 mg Alternative – Alkixen (Crizotinib) 250 mg Capsule | Everest Pharmaceuticals
Alkixen 250 mg (Crizotinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xalkori (Pfizer). It belongs to the ALK/ROS1 kinase inhibitor class and is used in selected ALK-positive or ROS1-positive non-small cell lung cancer.
Active ingredient: Crizotinib
Strength: 250 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Zejula 100 mg Alternative – Niranib (Niraparib) 100 mg Capsule | Everest Pharmaceuticals
Niranib 100 mg (Niraparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Zejula (GSK). It belongs to the PARP inhibitor class and is used in selected ovarian cancer maintenance treatment settings.
Active ingredient: Niraparib
Strength: 100 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.